reports
Oscar Haffen Lamm
- Oscar Haffen Lamm
BioInvent: Initiating coverage on a rising force in immuno-oncology wi...
BioInvent is a Swedish immuno-oncology company backed by a strong R&D platform that has been validated over the years through multiple strategic partnerships with leading pharma companies. Two lead assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcyRIIB), are progressing through clinical trials,
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.